NEXAVAR
Rs 78,400 vs Rs 7,750 medicine: Novartis, Eli Lilly oppose bid to cut breast cancer drug prices in India
Novartis and Eli Lilly have opposed a Kerala High Court petition seeking government intervention to make two breast cancer drugs cheaper, despite their India sales accounting for less than 0.5% of global revenues. Court submissions have highlighted development, clinical-trial and manufacturing costs against the medicines’ prices in India.
Natco Pharma's partner MylanInc gets USFDA nod for cancer drug
The company's marketing partner Mylan Inc has received a tentative approval from the United States Food and Drug Administration (USFDA).
Natco Pharma's US partner Mylan files application with USFDA
Natco Pharma's marketing partner Mylan Inc has filed an application with the US health regulator for generic Sorafenib tablets used mainly for treatment of liver and kidney cancers.
Nexavar Licence Case: SC dismisses Bayer’s appeal against HC decision
Bombay HC in July refused to revoke a compulsory licence issued to India’s Natco Pharma to sell a version of the German drug major’s kidney-cancer drug Nexavar
Bayer challenges IPAB’s compulsory licence order to Natco Pharma on cancer drug Nexavar
“We introduce the product after years of research and investment, while companies like Natco merely copy and manufacture the product,” said Ravi Kadam.
Natco Pharma awarded the compulsory licence to manufacture Bayer's cancer drug Nexavar
Out of the total analyst recommendations, 5 are buy and one is a sell. The average target price is Rs 530 - 22% more from the current market price.
- Go To Page 1
Intellectual board upholds CL to Natco for cancer drug
The IPAB has upheld the compulsory licence issued to Natco Pharma for production and marketing of generic version of cancer drug Nexavar.
IPAB allows Natco Pharma to sell Nexavar; stock gains
'Company will continue to market and sell the drug post verdict. It sold Rs 14 crore worth of Nexavar drug in the past 9 months.'
Bayer says it will defend its intellectual property rights on cancer drug
Bayer today said it will continue to defend its IP rights while expressing disappointment at the IPAB decision to reject the firm's plea to stay the compulsory license granted to Natco.
Patent drug prices to be set in negotiations with pharma companies
A panel set up to look into the pricing mechanism for patented drugs has said that prices have to be decided after deliberations with manufacturers.
Intellectual Property Appellate Board postpones Bayer's compulsory licence appeal
IPAB has postponed German company Bayer AG's appeal against the grant of a compulsory licence of its patented drug Nexavar to Natco Pharma to September 3
US accuses India of WTO rules violation over Nexavar: Report
The government had defended the move, with Commerce and Industry Minister Anand Sharma stating that India did not violate any WTO norms.
US threatens to take India to WTO over Nexavar Generic
The US has threatened to drag India to the WTO for issuing the firstever compulsory licence to a domestic company to manufacture generic version of Bayer's cancer drug Nexavar.
US ups the ante on Nexavar Generic, threatens to take India to WTO
The US House of Representatives and the US Patent and Trademark Office (USPTO) have threatened to drag India to the WTO.
Bayer demands withdrawal of Natco Pharma's compulsory licence
In March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's price.
Cipla breached patent rights by slashing cancer drug price: Bayer Pharma
Bayer has not given its consent to Cipla to launch its generic Sorafenib & co's decision to cut price "is clear patent infringement," Bayer spokesperson said.
Patented drugs: No application pending for compulsory license, says government
Amid concerns that more domestic pharma companies could seek compulsory licenses to replicate patented drugs, the government said no such application is pending for approval.
Bayer challenges Nexavar generic licence order
Bayer has filed an appeal against a patents order, which allowed domestic drug maker Natco Pharma to sell a generic version of the German firm's cancer drug 'Nexavar' in India.
Natco examining other drugs to identify compulsory license targets
We have mostly targeted unaffordable life saving drugs which are either unavailable or in-adequately available at an exorbitant cost. These are mostly recent innovations of early 2000s. .
Pharma industry split over nod to Natco to sell Bayer's cancer drug
The decision to allow Natco Pharma to sell Bayer's patented cancer drug Nexavar has divided the pharmaceutical industry.
Natco Pharma bags licence to sell Nexavar drug; stock up
Shares of Natco Pharma extended gains for the second straight day on Tuesday after the company reported that it had received a license for the generic version of Nexavar.
Natco may seek compulsory licence for Bayer's cancer drug
Natco Pharma plans to seek a compulsory licence to make Bayer AG's Nexavar in India, invoking a provision in local laws that allows generic drugmakers to make & sell patented drugs cheaply if medicine is unaffordable.
Bayer drags Cipla to court over patent
German drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based company from selling its generic version of controversial cancer medicine Nexavar (chemical name Sorafenib Tosylate).
SC rejects Bayer’s plea to stay Cipla’s cancer clone
The Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Bayer’s patented cancer medicine Nexavar while admitting the case.
No interim stay on Cipla’s Nexavar clone
The Supreme Court turned down a request by German drugmaker Bayer AG to stop Mumbai-based Cipla from launching the low-cost version of Bayer’s patented cancer medicine Nexavar while admitting the case.
HC rejects Bayer plea on Nexavar copycat
The Delhi HC dismissed an appeal by German drugmaker Bayer that sought to stop Cipla from obtaining a marketing approval from the country’s drug regulator to launch a low-cost version of patented cancer drug Nexavar in India.
Bayer’s bid to stay Cipla cancer drug foiled, next hearing on Oct 6
Germany's largest drug maker Bayer failed to get a court stay on Cipla from seeking permission to launch the European company’s copycat of cancer treating drug, Nexavar, in India.
Cipla's clone of Bayer cancer drug gets nod
This case was keenly watched by both pharma industry and health activists because it had much wider ramifications.
Major win for Indian pharma cos as HC dismisses Bayer petition
The Delhi High Court (HC) on Tuesday dismissed German drug major Bayer Healthcare’s attempt to stop Drug Controller General of India (DCGI) from giving marketing approval to Indian company Cipla for the generic version of Bayer’s patented kidney cancer drug, Nexavar.
Load More
